keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant in lung cancer

keyword
https://www.readbyqxmd.com/read/29752325/sequential-versus-concurrent-chemoradiation-therapy-by-surgical-margin-status-in-resected-non-small-cell-lung-cancer
#1
Vivek Verma, Amy C Moreno, Waqar Haque, Penny Fang, Steven H Lin
Background: Postoperative chemoradiotherapy (CRT) for non-small cell lung cancer (NSCLC) can be delivered sequentially (sCRT) or concurrently (cCRT). Without high-volume data, current guidelines recommend either option for patients with negative margins (M-) and cCRT for those with positive margins (M+). In this study, survival was compared between sCRT versus cCRT for M- and M+ disease; survival in patients who underwent sCRT was also assessed with chemotherapy-first versus radiotherapy (RT)-first. Methods: The National Cancer Database was queried for patients with primary NSCLC undergoing surgery followed by CRT...
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29749320/combined-treatment-for-gastric-cancer-immunological-approach
#2
Olzhas Zhandossov, Galina Kaussova, Avraam Koten
BACKGROUND/AIMS: Gastric cancer is one of the most common oncological diseases. It can develop in any part of the stomach and spread to other organs, especially the esophagus, lungs, and liver. The aim of our study was to investigate the effectiveness of our proposed therapy. MATERIALS AND METHODS: Our research promises more effective neoadjuvant therapy, including immunotherapy and multi-agent chemotherapy. Of the 62 patients involved in our study, 32 underwent neoadjuvant chemotherapy in combination with surgery, whereas the rest underwent neoadjuvant chemoimmunotherapy with surgery...
March 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29718155/robotic-resection-of-stage-iii-lung-cancer-an-international-retrospective-study
#3
Giulia Veronesi, Bernard Park, Robert Cerfolio, Mark Dylewski, Alpert Toker, Jacques P Fontaine, Wael C Hanna, Emanuela Morenghi, Pierluigi Novellis, Frank O Velez-Cubian, Marisa H Amaral, Elisa Dieci, Marco Alloisio, Eric M Toloza
OBJECTIVES: Minimally invasive surgery is accepted for early-stage lung cancer, but its role in locally advanced disease is controversial, especially using a robotic platform. The aim of this retrospective study was to assess the safety and effectiveness of robot-assisted resection in patients with Stage IIIA non-small-cell lung cancer (NSCLC) or carcinoid tumours in the series as a whole and in different subgroups according to adjuvant treatment. METHODS: This was a retrospective multicentre study of consecutive patients with clinically evident or occult N2 disease (210 NSCLC and 13 carcinoid) who, in 2007-2016, underwent robot-assisted resection at 7 high-volume centres...
April 30, 2018: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29703826/neoadjuvant-endpoints-response-criteria-proposed
#4
(no author information available yet)
Lung cancer experts propose using immune-related pathologic response criteria to evaluate lung tumors in neoadjuvant trials of checkpoint inhibitors, and suggest using major pathologic response as a surrogate endpoint for all preoperative lung cancer studies.
April 27, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29690894/uniportal-video-assisted-thoracoscopic-surgery-following-neoadjuvant-chemotherapy-for-locally-advanced-lung-cancer
#5
Zhiqiang Yang, Chunbo Zhai
BACKGROUND: Several retrospective studies have confirmed that video-assisted thoracoscopic surgery (VATS) following neoadjuvant chemotherapy is a safe and feasible treatment for advanced non-small cell lung cancer patients. As a minimally invasive technique, VATS usually leads to better clinical outcomes and better compliance with adjuvant treatment than conventional thoracotomy. Uniportal VATS (U-VATS) as an alternative option to conventional multi-port VATS has attracted much attention recently because reduced number and size of incisions may help to decrease inflammatory response and reduce postoperative pain for patients...
April 24, 2018: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29684314/efficacy-of-endosonographic-procedures-in-mediastinal-re-staging-of-lung-cancer-after-neoadjuvant-therapy-a-systematic-review-and-diagnostic-accuracy-meta-analysis
#6
Valliappan Muthu, Inderpaul Singh Sehgal, Sahajal Dhooria, Ashutosh N Aggarwal, Ritesh Agarwal
BACKGROUND AND AIM: The optimal modality for re-staging the mediastinum following neoadjuvant therapy for lung cancer remains unclear. Surgical methods are currently considered the reference standard. Herein, we evaluate the role of endosonographic techniques for mediastinal re-staging in lung cancer. METHODS: Systematic review of PubMed and EmBase databases was performed to identify studies utilizing endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) or a combination (CUS) for mediastinal re-staging following induction therapy for stage III lung cancer...
April 20, 2018: Chest
https://www.readbyqxmd.com/read/29680834/high-dose-radiotherapy-as-neoadjuvant-treatment-in-non-small-cell-lung-cancer
#7
Aaron M Allen, Tzippy Shochat, Dov Flex, Mordechai R Kramer, Alona Zer, Nir Peled, Elizabeta Dudnik, Eyal Fenig, Milton Saute
BACKGROUND: Trimodality therapy (chemoradiation followed by surgery) provides a benefit in progression-free survival but not overall survival. We sought to determine if a high dose of radiation could be delivered safely and provide a clinical benefit. METHODS: Consecutive patients with stage IIIA or IIIB non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy followed by surgery were reviewed with IRB approval. RESULTS: A total of 48 patients were treated from November 2007 to May 2014...
April 20, 2018: Oncology
https://www.readbyqxmd.com/read/29675791/chemotherapy-treatment-is-associated-with-altered-pd-l1-expression-in-lung-cancer-patients
#8
Lívia Rojkó, Lilla Reiniger, Vanda Téglási, Katalin Fábián, Orsolya Pipek, Attila Vágvölgyi, László Agócs, János Fillinger, Zita Kajdácsi, József Tímár, Balázs Döme, Zoltán Szállási, Judit Moldvay
OBJECTIVES: While the predictive value of programmed cell death ligand-1 (PD-L1) protein expression for immune checkpoint inhibitor therapy of lung cancer has been extensively studied, the impact of standard platinum-based chemotherapy on PD-L1 or programmed cell death-1 (PD-1) expression is unknown. The aim of this study was to determine the changes in PD-L1 expression of tumor cells (TC) and immune cells (IC), in PD-1 expression of IC, and in the amount of stromal mononuclear cell infiltration after platinum-based chemotherapy in patients with lung cancer...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29673125/major-pathologic-response-and-rad51-predict-survival-in-lung-cancer-patients-receiving-neoadjuvant-chemotherapy
#9
Apar Pataer, Ruping Shao, Arlene M Correa, Carmen Behrens, Jack A Roth, Ara A Vaporciyan, Ignacio I Wistuba, Stephen G Swisher
In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two genes and five protein biomarkers could predict MPR and OS in 98 patients with NSCLC receiving neoadjuvant chemotherapy. We collected formalin-fixed, paraffin-embedded specimens of resected NSCLC tumors from 98 patients treated with neoadjuvant chemotherapy...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29658848/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer
#10
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick, Richard J Battafarano, Moises J Velez, Natasha Rekhtman, Zachary Olah, Jarushka Naidoo, Kristen A Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, Justina X Caushi, Hok Yee Chan, John-William Sidhom, Robert B Scharpf, James White, Edward Gabrielson, Hao Wang, Gary L Rosner, Valerie Rusch, Jedd D Wolchok, Taha Merghoub, Janis M Taube, Victor E Velculescu, Suzanne L Topalian, Julie R Brahmer, Drew M Pardoll
Background Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. Methods In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose...
April 16, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29593890/neoadjuvant-and-consolidation-immuno-oncology-therapy-in-stage-iii-non-small-cell-lung-cancer
#11
REVIEW
Justin Yeh, Kristen A Marrone, Patrick M Forde
Lung cancer continues to be the leading cause of cancer death worldwide. Recently, immunotherapy for non-small cell lung cancer (NSCLC) has emerged as a powerful treatment option for advanced lung cancer. The relative success of programmed death 1 (PD-1) and/or programmed death ligand 1 (PD-L1) antibodies in metastatic disease have increased interest in expanding their use to earlier stage NSCLC. The complex and diverse nature of stage III disease also invites the incorporation of immunotherapy into treatment plans in both the neoadjuvant and consolidation settings...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29593886/immunotherapy-in-surgically-resectable-non-small-cell-lung-cancer
#12
REVIEW
Dwight Owen, Jamie E Chaft
Surgical resection is the mainstay of therapy for patients with resectable and operable early stage non-small cell lung cancer (NSCLC). Surgery alone yields an unacceptably high rate of lung cancer recurrence. The addition of chemotherapy to surgery as adjuvant or neoadjuvant treatment can improve survival rates by roughly 5% at 5 years. Recently, major advances in cancer immunotherapy have led to better outcomes for many patients with lung cancer. Monoclonal antibodies to programmed death 1 and its ligand are now approved for both first and second line treatment patients with metastatic lung cancer...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29593421/forecast-of-actin-binding-proteins-as-the-oncotarget-in-osteosarcoma-a-review-of-mechanism-diagnosis-and-therapy
#13
REVIEW
Yucheng Fu, Wei Yu, Hongliu Cai, Anwei Lu
Osteosarcoma (OS) is the most common bone malignant tumor with a high rate of lung metastasis and principally emerges in children and adolescents. Although neoadjuvant chemotherapy is widely used around the world, a high rate of chemoresistance occurs and frequently generates a poor prognosis. Therefore, finding a new appropriate prognostic marker for OS is a valuable research direction, which will give patients a better chance to receive proper therapy. Actin-binding proteins (ABPs) are a group of proteins that interact with actin cytoskeleton and play a crucial role in the regulation of the cell motility and morphology in eukaryotes...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29572004/phase-ii-trial-of-preoperative-pemetrexed-plus-carboplatin-in-patients-with-stage-ib-iii-nonsquamous-non-small-cell-lung-cancer-nsclc
#14
John D Hainsworth, David M Waterhouse, Kent C Shih, Ralph V Boccia, Victor M Priego, Michael J McCleod, Fred J Kudrik, Reed Brian Mitchell, Howard A Burris, F Anthony Greco, David R Spigel
OBJECTIVES: The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC. In this pilot phase II trial, we evaluated the feasibility of using pemetrexed and carboplatin as neoadjuvant therapy, prior to definitive surgical resection, for patients with localized NSCLC. PATIENTS AND METHODS: Patients with potentially resectable, previously untreated, clinical stage IB-III, nonsquamous NSCLC were eligible for this trial...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29571989/neoadjuvant-treatment-followed-by-surgery-versus-definitive-chemoradiation-in-stage-iiia-n2-non-small-cell-lung-cancer-a-multi-institutional-study-by-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-society
#15
F Couñago, N Rodriguez de Dios, S Montemuiño, J Jové-Teixidó, M Martin, P Calvo-Crespo, M López-Mata, M P Samper-Ots, J L López-Guerra, T García-Cañibano, V Díaz-Díaz, L de Ingunza-Barón, M Murcia-Mejía, P Alcántara, J Corona, M M Puertas, M Chust, M L Couselo, E Del Cerro, J Moradiellos, S Amor, A Varela, I J Thuissard, D Sanz-Rosa, B Taboada
OBJECTIVES: The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively debated in oncology. To evaluate the value of surgery in this patient population, we conducted a multi-institutional retrospective study comparing neoadjuvant chemoradiotherapy or chemotherapy plus surgery (CRTS) to definitive chemoradiotherapy (dCRT). MATERIAL AND METHODS: A total of 247 patients with potentially resectable stage T1-T3N2M0 NSCLC treated with either CRTS or dCRT between January 2005 and December 2014 at 15 hospitals in Spain were identified...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29559292/implications-of-pathologic-complete-response-beyond-mediastinal-nodal-clearance-with-high-dose-neoadjuvant-chemoradiation-therapy-in-locally-advanced-non-small-cell-lung-cancer
#16
Melissa A L Vyfhuis, Whitney M Burrows, Neha Bhooshan, Mohan Suntharalingam, James M Donahue, Josephine Feliciano, Shahed Badiyan, Elizabeth M Nichols, Martin J Edelman, Shamus R Carr, Joseph Friedberg, Gavin Henry, Shelby Stewart, Ashutosh Sachdeva, Edward M Pickering, Charles B Simone, Steven J Feigenberg, Pranshu Mohindra
PURPOSE: To determine, in a retrospective analysis of a large cohort of stage III non-small cell lung cancer patients treated with curative intent at our institution, whether having a pathologic complete response (pCR) influenced overall survival (OS) or freedom from recurrence (FFR) in patients who underwent definitive (≥60 Gy) neoadjuvant doses of chemoradiation (CRT). METHODS AND MATERIALS: At our institution, 355 patients with locally advanced non-small cell lung cancer were treated with curative intent with definitive CRT (January 2000-December 2013), of whom 111 underwent mediastinal reassessment for possible surgical resection...
February 13, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29525524/pattern-and-management-of-recurrence-of-mid-low-rectal-cancer-after-neoadjuvant-intensity-modulated-radiotherapy-single-center-results-of-687-cases
#17
Ai-Wen Wu, Yong Cai, Yong-Heng Li, Lin Wang, Zhong-Wu Li, Ying-Shi Sun, Jia-Fu Ji
BACKGROUND: The purpose of this study was to retrospectively analyze the pattern and the management of recurrence of rectal cancer treated with 22-fraction intensity-modulated radiation therapy (IMRT). PATIENTS AND METHODS: This study included patients who underwent IMRT with gross tumor volume of 50.6 Gy in 22 fractions with concurrent capecitabine treatment over a period of 30 days, after which the patients underwent total mesorectal excision at Peking University Cancer Hospital (2007-2015)...
March 7, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29520523/type-of-second-primary-malignancy-after-achieving-complete-response-by-definitive-chemoradiation-therapy-in-patients-with-esophageal-squamous-cell-carcinoma
#18
Toshifumi Yamaguchi, Ken Kato, Kengo Nagashima, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Tetsuya Hamaguchi, Yoshinori Ito, Jun Itami, Narikazu Boku, Kazuhide Higuchi
BACKGROUND: While the standard treatment for stage II-III (non-T4) esophageal squamous cell carcinoma (ESCC) is neoadjuvant therapy followed by esophagectomy, definitive chemoradiation therapy (dCRT) is an option to treat ESCC patients who reject or may not tolerate surgical treatment. Second primary malignancy (SPM) is a problem for long-term survivors after achieving complete response (CR) by dCRT. METHODS: The source of the subjects in this study was the patients with stage II/III (excluding T4 disease) ESCC (UICC6th) who underwent dCRT from 2000 to 2011 at the National Cancer Center Hospital, Japan...
March 8, 2018: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29515398/pulmonary-sarcoidosis-activation-following-neoadjuvant-pembrolizumab-plus-chemotherapy-combination-therapy-in-a-patient-with-non-small-cell-lung-cancer-a-case-report
#19
Ghina Fakhri, Reem Akel, Ziad Salem, Ayman Tawil, Arafat Tfayli
Background: Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor immune response by targeting programmed cell death 1 receptor. The use of pembrolizumab plus carboplatin/pemetrexed combination therapy results in improvement in overall survival and progression-free survival rates for non-small cell lung cancer (NSCLC) patients as compared to chemotherapy alone. However, numerous immune-mediated toxicities of pembrolizumab have been reported. Case Presentation: We report the case of a 74-year-old male patient diagnosed with stage IIIA programmed death-ligand 1-positive non-small cell lung adenocarcinoma treated with 4 cycles of carboplatin/pemetrexed plus pembrolizumab combination therapy followed by 2 cycles of pembrolizumab treatment...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29510431/non-small-cell-lung-cancer-with-chest-wall-involvement-integrated-treatment-or-surgery-alone
#20
Marco Chiappetta, Dania Nachira, Maria Teresa Congedo, Elisa Meacci, Venanzio Porziella, Stefano Margaritora
BACKGROUND:  The aim of this study was to identify prognostic factors in patients affected by non-small cell lung cancer (NSCLC) with chest wall (CW) involvement, analyzing different strategies of treatment and surgical approaches. METHODS:  Records of 59 patients affected by NSCLC with CW involvement underwent surgery were retrospectively reviewed, from January 2000 to March 2013. RESULTS:  Induction therapy was administered to 18 (30...
March 6, 2018: Thoracic and Cardiovascular Surgeon
keyword
keyword
52784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"